Several Innovations have emerged in the field of portable kidney dialysis that promise to make dialysis easier, more convenient and improve patient outcomes. We discuss the macro-trends in the dialysis market and highlight some of the technologies enabling this shift.
Since their discovery in 1895, X-rays have given us the power to “see” inside everything from buildings to the inner workings of the human body. Successive advancements to improve x-ray imaging have sparked exponential changes in a range of industries, especially in healthcare. However, there has always been a trade-off between dose and image quality: low radiation doses are safer but result in reduced quality images, while high doses are toxic and damaging. Here, we highlight innovations in a diversity of fields in the quest to develop advanced X-ray imaging systems that provide the holy grail of high-resolution and low radiation dose in a scalable device.
The recent success of messenger RNA (mRNA)-based vaccines in response to the COVID-19 pandemic has reignited research interest in RNA therapeutics. Given that RNA therapeutics are expected to advance and play an integral role in the development of novel drugs for human diseases in the future, we discuss the impact and challenges this technology will have.
The world has been pushing for the energy transition from carbon-heavy fossil fuels like oil and coal to clean energy sources so as to reduce the threat of climate change. But since the invasion of Ukraine by Russia, dependence on Russian gas has inspired a sudden push for energy independence via renewables, especially in Europe. We discuss the recent trends in energy and investing in technologies to power our future.
Last year was a boom year for SPAC deals, but public equity markets have been rocky since the beginning of 2022. There are numerous headwinds for SPACs, including a PIPE market in hibernation, high redemption rates and many SPACs trading down. SPAC investor interest is waning. Times are extremely tough right now for SPACs searching for targets, and many deals have failed to reach fruition.
